CRISPR Therapeutics AG
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M |
| Research and development | $284.8M | $310.2M | $387.3M | $461.6M | $340.6M |
| Operating expenses | $668.1M | $503.9M | $593.7M | $674.4M | $541.4M |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M |
| Pretax income | -$578.0M | -$362.7M | -$150.7M | -$650.5M | $379.5M |
| Income tax expense | $3.6M | $3.6M | $2.9M | -$325,000 | $1.9M |
| Net income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M |
| Balance Sheet | |||||
| Cash and equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M |
| Current assets | $2.0B | $1.9B | $1.9B | $1.9B | $2.4B |
| Total assets | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B |
| Current liabilities | $149.1M | $87.8M | $108.8M | $121.1M | $119.9M |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M |
| Stockholders' equity | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B |
| Cash Flow Statement | |||||
| Cash from operations | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M |
| Depreciation and amortization | $19.5M | $19.3M | $19.8M | $24.2M | $18.0M |
| Stock-based compensation | $72.5M | $86.6M | $81.0M | $97.9M | $102.4M |
| Capital expenditure | $914,000 | $1.9M | $9.5M | $37.2M | $81.7M |
| Free cash flow | -$345.9M | -$144.7M | -$269.8M | -$532.9M | $457.3M |
Shares outstanding 96.4M · Free float 81.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.